Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Brexpiprazole in Bipolar I Disorder
NCT03287869Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Oct 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of brexpiprazole in bipolar I disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Oct 2017; status: completed.
02
Drugs
brexpiprazole
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT03287869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03287869.